Radial Artery Occlusion After Endovascular Procedure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2168 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-31

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational cohort registry: prospective, multicenter independent evaluation of patients who undergo coronary angiography and/or PCI via radial artery. The purpose of this registry is to set the incidence of RAO according to ACT values, considered both as continuous and ordinal variable and its determinants. Coronary angiography and PCI will be performed according to usual practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Palmar Arch Insufficiency as a Risk Factor for Radial Artery Occlusion After Transradial Catheterization

NCT03993834

Coronary Artery Disease

COMPLETED

Strategies to Maintain Radial Artery Patency Following Diagnostic Coronary Angiography - Diagnostic Transradial Coronary Angiography Without Systemic Anticoagulatio

NCT04301921

Patients Undergoing Diagnostic Coronary Angiography

UNKNOWN NA

Evaluation of the Treatment of Abdominal Aortic Pathology With Hostile Necks, Para-/Juxra-renal and Sovrarenal Pathology at Short, Mid and Long Term

NCT03608683

Proximal Abdominal Aortic Aneurysms

COMPLETED

A Study of Structure and Function of Radial Artery After Transradial Coronary Intervention

NCT02831322

Intervention Transradial

COMPLETED NA

Prevalence of Distal Radial Artery Occlusion in Cardiovascular Catheterization Via Distal Radial Access

NCT05317533

Catheterization Complications Distal Radial Artery

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Trial objectives and purposes

Our objective was to evaluate:

i. relationship between activated clotting time (ACT), measured before sheath removal and incidence of radial artery occlusion (RAO), assessed by continuous Doppler and confirmed by echoDoppler before discharge from the hospital.

ii. the relationship between RAO and other clinical and procedural characteristics, to assess independent predictors of RAO.

Trial design:

Observational cohort registry: prospective, multicenter independent evaluation of patients who undergo coronary angiography and/or PCI via radial artery. The purpose of this registry is to set the incidence of RAO according to ACT values, considered both as continuous and ordinal variable and its determinants. Coronary angiography and PCI will be performed according to usual practice.

Patient population:

All patients referred for coronary angiography and/or with planned radial access will be invited to participate.

If the radial puncture is not possible (precluding the use of radial artery as vascular access) the patient will be excluded from the registry.

Primary end-point:

incidence of RAO before discharge.

Secondary end-points:

i. incidence of symptoms related to vascular access ii. incidence of significant forearm hematoma iii. incidence of pseudoaneurysm at site of vascular access iv. incidence of procedural success v. MACCEs at 12 months

Definition:

i. RAO: no flow detectable at continous Doppler at the site of vascular access, confirmed by echoDoppler; ii. symptoms: hand pain or paresthesiae after radial cannulation; iii. hematoma: local bleeding extending \> 15 cm2 on forearm iv. pseudoaneurysm: local ectasia of vessel wall not involving all the three layers at the site of puncture, diagnosed by 2D echoDoppler; v. procedural success: insertion of vascular sheath in the radial artery vi. Major cardiovascular cerebral events (MACCEs): death, cardiovascular death, myocardial infarction, any unplanned coronary revascularization, stroke/transient ischemic attack (TIA).

Subjects:

2168 consecutive patients in 5 centers (Divisione di Cardiologia, Ospedale Civile, Mirano (VE); Divisione di Cardiologia, Ospedale Civile, Conegliano (TV); Divisione clinicizzata di Cardiologia, Azienda ospedaliera-universitaria, Verona (VR); Divisione di Cardiologia, Ospedale Mater Salutis, Legnago (VR), Divisione di Cardiologia, Ospedale Santa Maria della Misericordia, Rovigo (RO), Istituto Clinico Humanitas, Milano) will be enrolled during a study period of 12 months. An interim analysis at 1084 patients will be performed. Inclusion and exclusion criteria will be applied to suitability for enrollment.

Evaluations:

Assessment of patency: whitin 24 hours from end of procedure or before discharge from the hospital, a physician blinded to ACT values will assess presence of flow along the radial artery with continous Doppler probe or with color Doppler probe (patency of radial artery will be considered if antegrade flow is present during contemporary compression of ulnar artery at the wrist); if a Doppler probe is used, a confirmation of occlusion with color Doppler must be obtained (see Appendix); in case of weak/biphasic flow with Doppler, an evaluation with color Doppler must be obtained to detect a segmental stenosis. Physicians will perform Doppler and echoDoppler evaluation after adequate training. Anonymized echoDoppler images will be recorded and send to referral center where the angiologist will review the images confirming the RAO.

Follow-up: if RAO occurs, 1 hour occlusion of homolateral ulnar artery could be attempted in order to increase flow and restore patency in occluded radial artery (25); if RAO persists, LMWH (100 u/Kg x 2/die) should be administered for 14-30 days (6). EchoDoppler follow-up at 1-3 months will be performed to check patency of occluded radial artery.

Long-term follow-up: a 12 months telephone call will be performed in order to assess MACCEs (death, cardiovascular death, myocardial infarction, stroke/TIA)

Statistics and data analysis:

The null hypothesis is that degree of anticoagulation (as assessed by ACT) has not relation with RAO. Alternative hypothesis is that incidence of RAO varies according to ACT values. Assuming a 6% of incidence of RAO at 24 hours, 95% confidence intervals would be 5% to 7% for a 2168-patient sample (110-151); PCIs must be at least 50% of the procedures, and enrollment should not stopped until at least 110 primary events (RAO) have occurred. An-interim analysis at 1084 patients enrolled will be performed. This sample size should allow evaluation of correlation of ACT with RAO both as continuous and ordinal variable. A statistical model (non-linear regression) will be fitted to the relation between RAO and ACT values. Receiver-operating characteristic (ROC) cut-off values will be obtained according to the best compromise between sensitivity and specificity, and a threshold effect will be investigated. To adjust for confounders, multivariate logistic regression analysis will be performed, considering the presence of RAO as dependent variable. In addition to ACT values (setting the group with lowest incidence as reference), other 4 variables known to be related with RAO will be entered into the model (heparin dosage, postprocedural compression time, patent hemostasis, sheath size) and odds ratios with 95% confidence intervals will be calculated. An exploratory analysis regarding possible role of other variables (sex, spasmolytic drugs, procedural time, multiple procedures, hemostasis device, pressure before sheath removal, antiGP IIb/IIIa drugs) will be performed. Pre-planned analysis of RAO incidence according to ACT values will be performed in these subgroups: patients who underwent coronary angiography vs patients who underwent PCI, patients in whom patent hemostasis was possible vs patients in whom patent hemostasis was not possible, patients with acute coronary syndrome vs without. Kaplan-Meier curves of MACCEs within 12 months after procedures according to RAO occurence will be plot and compared using log-rank statistics and Cox regression, adjusting for age, acute coronary syndrome and diabetes. Normality of data distribution will be assessed by skewness and kurtosis and by linear plot graph. Data will be reported as mean±standard deviation or median and interquartile range according to distribution. Chi-squared statistics will be used for categorical variables, and the t-test or Mann-Whitney U test for scale variables if data followed normal or non-normal distribution, respectively. Post-test Bonferroni correction and Dunn's test will be used for pairwise comparisons among groups. Statistical significance will be set at p\<0.05 (two-tailed) for all tests. All data will be analysed using Prism (version 5, Graphpad, California) or SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Embolism and Thrombosis of the Radial Artery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ACT < 150 sec

patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal below 150 sec

heparin

Intervention Type DRUG

routinary heparin administration during coronary angiography/PCI

ACT between 150 and 249 sec

patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal between 150 and 249 sec

heparin

Intervention Type DRUG

routinary heparin administration during coronary angiography/PCI

ACT >= 250 sec

patients who received 5000 U of heparin (in coronary angiography) or according to weight (in PCI) and having ACT value before sheath removal above 250 sec

heparin

Intervention Type DRUG

routinary heparin administration during coronary angiography/PCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

heparin

routinary heparin administration during coronary angiography/PCI

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \- Patients \> 18 years
2. \- Planned transradial endovascular procedure
3. \- Written informed consent signed by the patient as approved by the Ethics Committee

Exclusion Criteria

1. Planned femoral access
2. Impossible bilateral radial puncture.
3. Anticipated impossible assess of radial patency (for example: patient transferred to other hospital immediately after the procedure)
4. use of bivalirudin as anticoagulant during PCI
5. use of low-molecular weight heparin (LMWH) within 12 hours from the PCI
6. INR \> 2
7. Participation in another medical research study within 3 months of study enrollment
8. The patient has a co-morbidity that reduces life expectancy to \< 1 month
9. Positive pregnancy assessment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No